Mercredi, 8 Avril 2020
Dernières nouvelles
Principale » Diplomat Pharmacy, Inc. (NYSE:DPLO) Releases FY17 Earnings Guidance

Diplomat Pharmacy, Inc. (NYSE:DPLO) Releases FY17 Earnings Guidance

23 Novembre 2017

Diplomat Pharmacy posted earnings of $0.21 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 28.6%. The company provided earnings per share guidance of $0.82-0.87 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.75.

TRADEMARK VIOLATION WARNING: "Diplomat Pharmacy, Inc".

Wall Street analysts, on average, are forecasting the company's EPS to be 0.17, compared to 0.15 reported in the same quarter past year. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. EPS ratio determined by looking at last 12 month figures is 0.12. The company issued revenue guidance of $4.4-4.6 billion, compared to the consensus revenue estimate of $4.52 billion. PNC Financial Services Group Inc. grew its stake in shares of Diplomat Pharmacy by 46.7% during the second quarter. "Increased by William Blair (DPLO)" was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark and copyright legislation.

Diplomat Pharmacy Inc (NYSE:DPLO)'s revenue estimates for the current quarter are $1.16 Billion according to 10 number of analysts, for the current quarter the company has high revenue estimates of $1.18 Billion in contradiction of low revenue estimates of $1.11 Billion. Robert W. Baird reiterated a buy rating and issued a $20.00 price objective on shares of Diplomat Pharmacy in a report on Sunday, September 17th.

The stock is now showing YTD performance of 26.51 Percent. Needham & Company LLC raised their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the stock a "buy" rating in a research note on Wednesday, November 8th. BidaskClub lowered Diplomat Pharmacy from a "buy" rating to a "hold" rating in a research note on Thursday, November 9th. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to sentiments of 10 analysts the mean estimates of short term price target for the company's stock is marked at $19.4.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, August 7th. The company had a trading volume of 866,538 shares, compared to its average volume of 811,648.

Coleman re-commits to Wallabies with Rebels move
Coleman is the 11th former Western Force player to move to Melbourne after the former were stripped of their licence for the 2018 season.

Diplomat Pharmacy Inc (NYSE:DPLO) 52-week high price stands at $21.99 and low price stands at $12.25, its price distance from 52-week high is -27.51% while its distance from 52-week low price is 30.12%. The company's previous year sales total was 1.14 Million. The company has a market cap of $1,200.00, a PE ratio of 20.70, a P/E/G ratio of 2.87 and a beta of 0.74.

Institutional investors have recently made changes to their positions in the business. Relative strength index (RSI-14) for Diplomat Pharmacy Inc (NYSE:DPLO) is at 40.01.

This particular stock's 5-day moving average is 16.81, its 20-day moving average is 19.59 and its 100-day moving average is 18.07. State of Alaska Department of Revenue now owns 8,623 shares of the company's stock worth $127,000 after purchasing an additional 3,833 shares in the last quarter. Northern Trust Corp increased its stake in Diplomat Pharmacy by 95.1% in the 2nd quarter. Municipal Employees Retirement System of MI now owns 10,250 shares of the company's stock worth $152,000 after purchasing an additional 480 shares during the period. Municipal Employees Retirement System of MI increased its position in shares of Diplomat Pharmacy by 4.9% in the second quarter. Dimensional Fund Advisors LP now owns 894,669 shares of the company's stock worth $18,528,000 after acquiring an additional 536,412 shares during the last quarter. Hedge funds and other institutional investors own 67.74% of the company's stock.

In other Diplomat Pharmacy news, President Joel Saban bought 10,000 shares of the firm's stock in a transaction on Monday, November 20th. Municipal Employees Retirement System of MI now owns 10,250 shares of the company's stock worth $152,000 after acquiring an additional 480 shares in the last quarter. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Atul Kavthekar bought 2,000 shares of the firm's stock in a transaction on Monday, November 20th. The shares were bought at an average cost of $15.24 per share, with a total value of $152,400.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares of the company's stock, valued at approximately $30,000. The disclosure for this purchase can be found here.

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers.

The specialty pharmacy said on Wednesday that it would buy Missouri-based pharmacy benefit manager LDI Integrated Pharmacy Services for $388 mln in cash and $80 mln in stock.